Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer

BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differenti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Martin, Petra, Noonan, Sinead, Mullen, Michael P, Scaife, Caitriona, Tosetto, Miriam, Nolan, Blathnaid, Wynne, Kieran, Hyland, John, Sheahan, Kieran, Elia, Giuliano, O’Donoghue, Diarmuid, Fennelly, David, O’Sullivan, Jacintha
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4289341/
https://ncbi.nlm.nih.gov/pubmed/25428203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-887
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki